Categories Earnings, LATEST, Other Industries
Stryker confirms that it didn’t bid for Boston Scientific
Two days after the acquisition speculation sparked in the internet, medical equipment maker Stryker (SYK) stated today in an 8-K filing that it is “not in discussions with Boston Scientific Corporation (BSX) regarding a potential acquisition.”
On June 11, WSJ had reported that Stryker had offered to buy Boston Scientific, which made the latter’s shares shoot to its 52-week new high. On contrary, Stryker ended in red on Monday. Trading of both the companies’ shares was stopped for a while because of high volatility.
Related: Boston Scientific spikes to new 52-week high on takeover rumors
Earlier, both Stryker and Boston Scientific abstained from commenting on the deal. But today the Kalamazoo, Michigan-based medical tech company has confirmed officially that it is not interested in buying Boston Scientific. There are also rumors going around that Johnson & Johnson (JNJ) might bid on the Marlborough, Massachusetts-based company.
Considered one of the megadeals if happened, this acquisition would have created a combined company that would have had revenue of $25 billion in 2019, according to RBC analyst Glenn Novarro.
On Stryker’s confirmation that the deal was not happening, the company’s shares rose about 7% and Boston Scientific stock dropped around 7% during pre-market trading today. When the market opened up, Stryker and Boston Scientific continued the same trend.
Most Popular
Microsoft (MSFT) reports higher revenue and profit for Q3 2024
Microsoft Corp. (NASDAQ: MSFT) on Thursday said its third-quarter 2024 earnings increased year-over-year, reflecting strong performance by the tech giant’s main operating segments. Third-quarter revenues came in at $61.86 billion,
GOOG, GOOGL Earnings: All you need to know about Alphabet’s Q1 2024 earnings results
Alphabet Inc. (NASDAQ: GOOG, GOOGL) reported its first quarter 2024 earnings results today. Revenues increased 15% year-over-year to $80.5 billion. Revenue growth was 16% in constant currency. Net income was
MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided by an increase in revenues. First-quarter worldwide sales